Recent Finacing
Recent Raise
Corlieve Therapeutics develops AAV9-based gene therapies for severe neurological disorders, advancing a refractory temporal lobe epilepsy program built on INSERM/CNRS/Aix‑Marseille/Bordeaux science and licensed REGENXBIO NAV AAV9 technology.
